Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05038371 · ClinicalTrials.gov registry record
Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration
A clinical trial, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- 20
- Enrollment target
NCT05038371: Clinical Trial study, sponsored by Johns Hopkins University.
NCT05038371 is a clinical trial that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05038371 was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- 20 participants
- Enrollment target
Study Summary
Age-related macular degeneration (AMD) remains a leading cause of blindness in United States and can be broadly divided into two forms: non-neovascular AMD (NNVAMD) and neovascular AMD (NVAMD) AMD. Among the several mechanisms underlying AMD, hypoxia and oxidative stress have been implicated and cause upregulation of several signaling proteins. About 20% of patients with NNVAMD develop choroidal neovascularization and hence convert to NVAMD. Upregulation of vascular endothelial growth factor (VEGF) plays a critical role in conversion from NNVAMD to NVAMD. Connective tissue growth factor (CTGF) is a polypeptide that has been shown to be overexpressed in various fibrotic disorders, suggesting its involvement in scarring. After the development of choroidal neovascularization, subretinal fibrosis may occur and result in permanent reduction of vision. An important question is, does CTGF contribute to subretinal fibrosis. An important first step in addressing this question is to determine if CTGF levels are increased in the eyes of patients with NVAMD and this is the objective of this study. The investigators plan to measure levels of connective tissue growth factor (CTGF) in the aqueous humor of patients with neovascular age-related macular degeneration and compare to controls. Levels of VEGF will be measured as a positive control.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2022-09-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05038371
The ClinicalTrials.gov registry entry for NCT05038371 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05038371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05038371 about?
NCT05038371 is a clinical study titled "Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration". Age-related macular degeneration (AMD) remains a leading cause of blindness in United States and can be broadly divided into two forms: non-neovascular AMD (NNVAMD) and neovascular AMD (NVAMD) AMD. Among the several mechanisms underlying AMD, hypoxia and oxidative stress have been implicated and cau...
What is the current status of trial NCT05038371?
This trial is currently terminated. The enrollment target is 20 participants. The study started on 2021-09-01. Estimated completion is 2022-09-22.
Who is sponsoring clinical trial NCT05038371?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.